Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. (17th August 2020)

• Record Type: Journal Article
• Authors: Noble, Carl W.; Gangaputra, Sapna S.; Thompson, Ian A.; Yuan, Amy; Apolo, Andrea B.; Lee, Jung-Min; Papaliodis, George N.; Kodati, Shilpa; Bishop, Rachel; Magone, M. Teresa; Sobrin, Lucia; Sen, H. Nida
• Is Part Of: Ocular immunology and inflammation. Volume 28:Number 6(2020)
• Page Start: 854
• Page End: 859
• Publication Date: 2020-08-17
• Subjects: Adverse -- checkpoint -- events -- inflammation -- inhibitor; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1583347
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To report the clinical features, severity, and management of ocular immune-related adverse events (irAEs) in the setting of immune checkpoint inhibitor therapy for metastatic malignancies. Methods: Retrospective chart review at three tertiary ophthalmology clinics. Electronic medical records were reviewed between 2000 and 2017 for patients with new ocular symptoms while undergoing checkpoint inhibition therapy. Results: Eleven patients were identified. Ocular irAEs ranged from keratoconjunctivitis sicca to Vogt-Koyanagi-Harada-like findings. Average timing of irAEs from starting checkpoint inhibitor therapy was 15.7 weeks. Ocular inflammation was successfully controlled with corticosteroids in most cases, however three patients discontinue treatment as a result of ocular inflammation with decreased visual acuity, two discontinued due to progression of metastatic disease, and one discontinued due to severe systemic irAEs. Conclusion: We found a wide spectrum of ocular irAEs associated with immune checkpoint inhibitors. In most cases, ocular AEs did not limit ongoing cancer treatment.